|
|
Article: Sirna Therapeutics Licenses Seminal Intellectual Property in the Field of RNAi; Significant Addition to Sirna's Broad Patent Portfolio.
- Article from:
- PR Newswire
- Article date:
- September 9, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sirna Therapeutics, Inc. announced today that the company has entered into a worldwide license agreement with the University of Massachusetts Medical School for its undivided interest in the seminal intellectual property on RNA interference (RNAi) technology covering short interfering RNA (siRNA). This license significantly strengthens Sirna's broad RNAi intellectual property portfolio for the development of RNAi therapeutics.
The license covers the RNAi technology patent application filed by Tuschl et al., International PCT Publication No. WO 01/75164, which was jointly developed and is owned by the University of Massachusetts Medical School, Max-Planck ...